Separate names with a comma.
$ATAI TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit...
atai Life Sciences Awarded Grant from the National Institutes of Health 5-year UG3/UH3 grant will fund the optimization and early-stage...
Here are key updated facts (mid-2025) that are relevant: Phase 3 Program for MM120 ODT MindMed is running three pivotal Phase 3 trials for...
MM120 Effective as a Single Dose for Generalized Anxiety Disorder: Phase 2b Results | HCP Live Investigator Maurizio Fava, MD, chair of Mass...
H.C. Wainwright 27th Annual Global Investment Conference https://journey.ct.events/view/c1a22c93-1c8f-46ff-9ce2-c47ba55fb424
Psychedelic drug popular in 1960s could ease anxiety as doctors share warnings (Fox News)...
LSD-Based Med Safe, Effective for Anxiety in Phase 2B Trial (MedScape)...
'One and done' dose of LSD keeps anxiety at bay (NPR)...
Psychedelic Medicine Is Moving from Promise to Proof: Three Things You Should Know...
Corporate Presentation - September 2025 https://www.publicnow.com/view/D32F6090EDA4933F11C1AFB738B5ED9980DB1AA1
Journal of the American Medical Association (JAMA) Publishes Results from First-Ever Randomized, Placebo-Controlled Clinical Trial Assessing the...
It will be more than that... I am thinking 6-10B
BioSpace Podcast - Lilly’s Obesity Pill Heads to the FDA, AbbVie Bets on Psychedelics, HHS Unveils More Change...
The Giglamesh buyout at $1.2B is just the first domino to fall in what will likely be a wave of consolidation in the psychedelic and CNS biotech...
[IMG]
Tapped 1 billion market cap today. Atai is moving to the US and once the stock hits 5.00 that is when institutions usually buy in and they get...
"At atai, we believe that collaborations and partnerships are key to driving innovation. We helped launch the atai Research Fellowship at...
